Global R&D Structure Close to Customers and Markets
First written in FY2016. 21 of 27 entries say "Restated". Latest entry: FY2026.
13 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Mirai-kan, the new R&D and manufacturing facility in operation since December 2022, consolidates the production of biomedical products and R&D functions. It will enhance the competitiveness of medical collagen and gelatin in terms of quality, cost and production volume, contributing to the medicine of the future. Mirai-kan also brings together researchers from across the company's fields, including collagen peptides and food ingredients, as well as biomedicine. By generating new innovations through combining the knowledge and information obtained there, the company aims to create technologies and products that will drive growth across the company.」
The company plans to continue operating Mirai-kan as an R&D and manufacturing base bringing together researchers from across the company, and to create technologies and products that will drive growth by combining expertise from different fields. R&D expenses were ¥1,206 million. - FY2026-H1RestatedAnnual report
「The amount of R&D activities for the group as a whole during the current interim consolidated accounting period was ¥570 million. There were no material changes in the status of the group's R&D activities during the current interim consolidated accounting period.」
The company stated that there were no material changes in R&D activities and disclosed R&D expenses of ¥570 million for the current interim consolidated accounting period. - FY2025AdvancedAnnual report
「Mirai-kan, the new R&D and manufacturing facility in operation since December 2022, consolidates the production of biomedical products and R&D functions. It will enhance the competitiveness of medical collagen and gelatin in terms of quality, cost and production volume, contributing to the medicine of the future.」
Mirai-kan has progressed from a completed facility to an R&D and manufacturing base operating since December 2022, bringing together researchers from fields beyond biomedicine and entering a stage focused on creating products and technologies across the company. - FY2025-H1RestatedAnnual report
「The amount of R&D activities for the group as a whole during the current interim consolidated accounting period was ¥592 million. There were no material changes in the status of the group's R&D activities during the current interim consolidated accounting period.」
The company stated that there were no material changes in R&D activities and disclosed R&D expenses of ¥592 million for the interim consolidated accounting period. - FY2024-Q3RestatedAnnual report
「The amount of R&D activities for the group as a whole during the third quarter of the current consolidated cumulative period was ¥1,013 million. There were no material changes in the status of the group's R&D activities during the third quarter of the current consolidated cumulative period.」
The company disclosed R&D expenses of ¥1,013 million and stated that there were no material changes in the status of R&D activities. - FY2024-Q2RestatedAnnual report
「The amount of R&D activities for the group as a whole during the second quarter of the current consolidated cumulative period was ¥684 million. There were no material changes in the status of the group's R&D activities during the second quarter of the current consolidated cumulative period.」
R&D expenses were ¥684 million, and it was stated that there were no material changes in the status of R&D activities. - FY2024-Q1RestatedAnnual report
「The amount of R&D activities for the group as a whole during the first quarter of the current consolidated cumulative period was ¥361 million. There were no material changes in the status of the group's R&D activities during the first quarter of the current consolidated cumulative period.」
The company stated that there were no material changes in R&D activities and disclosed cumulative first-quarter R&D expenses of ¥361 million. - FY2023-Q3AdvancedAnnual report
「In December 2022, the Company completed Mirai-kan, a new research, development and manufacturing building, consolidating the research and development and production functions for biomedical products and the research and development functions of all business divisions to create products leading to new businesses.」
In addition to the existing R&D structure close to customers and markets, the Mirai-kan research and manufacturing facility, which consolidates production of biomedical products and the research and development functions of all business divisions, was completed. - FY2023-Q2RestatedAnnual report
「The amount of R&D activities for the group as a whole during the second quarter of the current consolidated cumulative period was ¥473 million. There were no material changes in the status of the group's R&D activities during the second quarter of the current consolidated cumulative period.」
Cumulative R&D expenses for the second quarter were ¥473 million, and it was stated that there were no material changes in the status of R&D activities. - FY2022-Q3RestatedAnnual report
「The amount of R&D activities for the group as a whole during the third quarter of the current consolidated cumulative period was ¥688 million. There were no material changes in the status of the group's R&D activities during the third quarter of the current consolidated cumulative period.」
Cumulative R&D expenses for the third quarter were ¥688 million, and no material changes in the status of R&D activities were reported. - FY2022-Q2AdvancedAnnual report
「In September 2021, construction began on Mirai-kan, a new research building intended to strengthen the business base by consolidating biomedical product production and the research and development functions of all business divisions and creating products leading to new businesses. Completion was scheduled for autumn 2022.」
In addition to an R&D structure close to customers and markets, construction began on a new research building that will consolidate production of biomedical products and the research and development functions of all business divisions. - FY2022-Q1RestatedAnnual report
「The amount of R&D activities for the group as a whole during the first quarter of the current consolidated cumulative period was ¥203 million. There were no material changes in the status of the group's R&D activities during the first quarter of the current consolidated cumulative period.」
R&D expenses for the cumulative first-quarter period were ¥203 million, and no material changes in the status of R&D activities were reported. - FY2021AdvancedAnnual report
「In response to customer and market requirements, the group has established a structure that deploys sales, R&D and production staff across Japan, North America and Asia to enable a rapid response. Research staff actively conduct joint research and commissioned research with external research institutions and universities, and work to acquire expertise in basic research on materials and applied technologies. The company also holds technical discussions to promote and invigorate its R&D activities and improve its technical capabilities and knowledge.」
While continuing its customer-focused R&D structure centered on Japan, North America and Asia, rather than the former 5-country structure, the company is consolidating R&D functions, including biomedical R&D, and proceeding with construction of a new research building. - FY2021-Q2RestatedAnnual report
「The amount of R&D activities for the group as a whole during the second quarter of the current consolidated cumulative period was ¥463 million. There were no material changes in the status of the group's R&D activities during the second quarter of the current consolidated cumulative period.」
R&D expenses for the cumulative second-quarter period were ¥463 million, and it was stated that there were no material changes in the status of R&D activities. - FY2021-Q1RestatedAnnual report
「The amount of R&D activities for the group as a whole during the first quarter of the current consolidated cumulative period was ¥231 million. There were no material changes in the status of the group's R&D activities during the first quarter of the current consolidated cumulative period.」
R&D expenses were ¥231 million, and it was stated that there were no material changes in the status of R&D activities. - FY2020-Q2RestatedAnnual report
「The amount of R&D activities for the group as a whole during the second quarter of the current consolidated cumulative period was ¥524 million. There were no material changes in the status of the group's R&D activities during the second quarter of the current consolidated cumulative period.」
R&D expenses were ¥524 million, and no material changes in the status of R&D activities were reported. - FY2020-Q1RestatedAnnual report
「The amount of R&D activities for the group as a whole during the first quarter of the current consolidated cumulative period was ¥266 million. There were no material changes in the status of the group's R&D activities during the first quarter of the current consolidated cumulative period.」
R&D expenses for the cumulative first-quarter period were ¥266 million, and no material changes in the status of R&D activities were reported. - FY2019-Q3RestatedAnnual report
「The amount of R&D activities for the group as a whole during the third quarter of the current consolidated cumulative period was ¥784 million. On 1 August 2018, the company carried out a company split under which the company, excluding its adhesive business's manufacturing operations, was the splitting company and Bostik Nitta Co., Ltd. was the succeeding company, and at the same time discontinued its R&D activities for the adhesive business.」
Cumulative R&D expenses were ¥784 million, and the company continued in the state of having discontinued its R&D activities for the adhesive business in connection with the company split. - FY2019-Q2SoftenedAnnual report
「The amount of R&D activities for the group as a whole during the second quarter of the current consolidated cumulative period was ¥552 million. On 1 August 2018, the company carried out a company split under which the company, excluding its adhesive business's manufacturing operations, was the splitting company and Bostik Nitta Co., Ltd. was the succeeding company, and at the same time discontinued its R&D activities for the adhesive business.」
The company stated that it had discontinued its R&D activities for the adhesive business in connection with the company split, reducing the scope covered by its R&D structure. - FY2019-Q1RestatedAnnual report
「The amount of R&D activities for the group as a whole during the first quarter of the current consolidated cumulative period was ¥269 million. There were no material changes in the status of the group's R&D activities during the first quarter of the current consolidated cumulative period.」
R&D expenses were ¥269 million, and no material changes in the status of R&D activities were reported. - FY2018RestatedAnnual report
「To respond rapidly to requests from customers and markets, the group has established a structure that places sales, development and production staff across Japan, the United States, China, India and Vietnam. Research staff actively conduct joint research and commission research with external research institutions and universities, while also working to advance basic research on materials and acquire applied technologies.」
The group continues to operate an R&D structure that deploys sales, development and production staff across 5 countries and conducts joint research with external research institutions and universities. R&D expenses were ¥1,105 million. - FY2018-Q3RestatedAnnual report
「The Group's total research and development expenditure for the nine months ended the third quarter of the current fiscal year was ¥808 million. There were no material changes in the status of the Group's research and development activities during the nine months ended the third quarter of the current fiscal year.」
R&D expenses for the cumulative third-quarter period were ¥808 million, and no material changes in the status of R&D activities were reported. - FY2018-Q2RestatedAnnual report
「The amount of R&D activities for the group as a whole during the second quarter of the current consolidated cumulative period was ¥528 million. There were no material changes in the status of the group's R&D activities during the second quarter of the current consolidated cumulative period.」
R&D expenses for the cumulative second-quarter period were ¥528 million, and no material changes in the status of R&D activities were reported. - FY2018-Q1RestatedAnnual report
「The amount of R&D activities for the group as a whole during the first quarter of the current consolidated cumulative period was ¥254 million. There were no material changes in the status of the group's R&D activities during the first quarter of the current consolidated cumulative period.」
R&D expenses for the first quarter were ¥254 million, and no material changes in the status of R&D activities were reported. - FY2017RestatedAnnual report
「To respond rapidly to requests from customers and markets, the group has established a structure that places sales, development and production staff across Japan, the United States, China, India and Vietnam. Research staff actively conduct joint research and commission research with external research institutions and universities, while also working to advance basic research on materials and acquire applied technologies.」
The group continues to operate a cross-border R&D structure spanning its overseas sites, collaborate with external research institutions, and hold technical discussions. Total R&D expenses were ¥1,063 million for the consolidated fiscal year. - FY2017-Q3RestatedAnnual report
「The amount spent on R&D activities by the group during the cumulative nine-month period of the current fiscal year was ¥779 million. There were no material changes in the group's R&D activities during the cumulative nine-month period of the current fiscal year.」
The company stated that cumulative spending on R&D activities was ¥779 million and that there had been no material change in the status of those activities. - FY2016First statedAnnual report
「The company has established a structure that places sales, development and production staff across Japan, the United States, China, India and Vietnam, bringing customers and R&D organizations as close together as possible. While focusing research staff on production development and customer service, the company also actively conducts joint research and commissions research with external research institutions and universities, working to advance basic research on materials and acquire applied technologies.」
The company also referred to technical discussions since 2015, using overseas locations, proximity to customers and collaboration with external research organizations as means of advancing R&D.